Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 3 | 1 |
| List of Figures | 4 | 1 |
| Report Guidance | 5 | 1 |
| Clinical Trials by Region | 6 | 9 |
| Clinical Trials and Average Enrollment by Country | 7 | 3 |
| Top Five Countries Contributing to Clinical Trials in Asia-Pacific | 10 | 1 |
| Top Five Countries Contributing to Clinical Trials in Europe | 11 | 1 |
| Top Countries Contributing to Clinical Trials in North America | 12 | 1 |
| Top Five Countries Contributing to Clinical Trials in Middle East and Africa | 13 | 1 |
| Top Five Countries Contributing to Clinical Trials in Central and South America | 14 | 1 |
| Clinical Trials by G7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials | 15 | 1 |
| Clinical Trials by Phase in G7 Countries | 16 | 1 |
| Clinical Trials in G7 Countries by Trial Status | 17 | 1 |
| Clinical Trials by E7 Countries: Proportion of Hepatitis B to Infectious Disease Clinical Trials | 18 | 1 |
| Clinical Trials by Phase in E7 Countries | 19 | 1 |
| Clinical Trials in E7 Countries by Trial Status | 20 | 1 |
| Clinical Trials by Phase | 21 | 2 |
| In Progress Trials by Phase | 22 | 1 |
| Clinical Trials by Trial Status | 23 | 1 |
| Clinical Trials by End Point Status | 24 | 1 |
| Subjects Recruited Over a Period of Time | 25 | 1 |
| Clinical Trials by Sponsor Type | 26 | 1 |
| Prominent Sponsors | 27 | 3 |
| Top Companies Participating in Hepatitis B Therapeutics Clinical Trials | 28 | 2 |
| Prominent Drugs | 30 | 1 |
| Latest Clinical Trials News on Hepatitis B | 31 | 4 |
| Aug 02, 2016: ContraVir Reports Positive Data from Phase 1b Study of CMX157 | 31 | 1 |
| Jul 21, 2016: Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial s Safety Review Committee | 31 | 1 |
| Jun 22, 2016: Spring Bank Pharmaceuticals Doses the First Patient in the ACHIEVE Global Phase 2 Program of SB 9200 in Hepatitis B | 32 | 1 |
| Jun 21, 2016: ContraVir Doses First Patients in Head-to-Head Study of CMX157 vs. Viread for Treating Hepatitis B | 32 | 1 |
| Jun 07, 2016: Replicor announces publication of its REP 101 study demonstrating the therapeutic effect of NAPs and the achievement of functional control off treatment in human patients with chronic hepatitis B infection | 33 | 1 |
| Jun 07, 2016: Replicor announces publication of its REP 102 study demonstrating the therapeutic effect of NAPs and the achievement of functional control off treatment in human patients with chronic hepatitis B infection | 33 | 1 |
| Jun 01, 2016: ContraVir Initiates Head-to-Head Phase 2a Clinical Study of CMX157 vs. Viread for Treating Hepatitis B | 33 | 1 |
| Jun 01, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology | 34 | 1 |
| May 25, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start Of Second Phase 2 Clinical Trial Of Myrcludex B In Chronic Hepatitis B/D Infection | 34 | 1 |
| Clinical Trial Profile Snapshots | 35 | 747 |
| Appendix | 782 | 3 |
| Abbreviations | 782 | 1 |
| Definitions | 782 | 1 |
| Research Methodology | 783 | 1 |
| Secondary Research | 783 | 1 |
| About GlobalData | 784 | 1 |
| Contact Us | 784 | 1 |
| Disclaimer | 784 | 1 |
| Source | 785 | 1 |